Ryuji Okamoto

Prof. Dr. Ryuji Okamoto

Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RORyuji Okamoto
Ryuji Okamoto
YAYusuf Ali
Yusuf Ali
RHRyotaro Hashizume
Ryotaro Hashizume
NSNoboru Suzuki
Noboru Suzuki
MIMasaaki Ito
Masaaki Ito
Brain natriuretic peptide (BNP) is an important biomarker for patients with heart failure, hypertension and cardiac hypertrophy. Although it is known that BNP levels are relatively higher in patients with chronic kidney disease and no heart disease, the mechanism remains unknown. Here, we review the functions and the roles of BNP in the heart-kidney interaction. In addition, we discuss the relevant molecular mechanisms that suggest BNP is protective against chronic kidney diseases and heart failure, especially in terms of the counterparts of the renin-angiotensin-aldosterone system (RAAS). The renal medulla has been reported to express depressor substances. The extract of the papillary tips from kidneys may induce the expression and secretion of BNP from cardiomyocytes. A better understanding of these processes will help accelerate pharmacological treatments for heart-kidney disease.

31 January 2008 in Atherosclerosis
Verified
Journal Article
Closed access
HIHitoshi Iwasaki
Hitoshi Iwasaki
RORyuji Okamoto
Ryuji Okamoto
SKShinya Kato
Shinya Kato
KKKatsuhisa Konishi
Katsuhisa Konishi
HMHideo Mizutani
Hideo Mizutani
MIMasaaki Ito
Masaaki Ito

13 October 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RORyuji Okamoto
Ryuji Okamoto
IGItaru Goto
Itaru Goto
Yuhei NishimuraYuhei Nishimura
Yuhei Nishimura
IKIssei Kobayashi
Issei Kobayashi
RHRyotaro Hashizume
Ryotaro Hashizume
KDKaoru Dohi
Kaoru Dohi
GJB4 encodes a transmembrane connexin protein (Cx30.3) that is a component of gap junctions. This study investigated whether GJB4 plays an important role in human heart disease and function. We examined a patient and her older brother who both presented with complicated severe hypertrophic cardiomyopathy (HCM) and whose parents are healthy married cousins. The gene exome analysis showed 340 single nucleotide polymorphisms (SNPs) that caused amino acid changes for which the patient was homozygous and both parents were heterozygous. After excluding all known common (>10%) SNP gene mutations, the gene for GJB4 was the only identified gene that is possibly associated with cardiac muscle. The resultant E204A substitution exists in the 4th transmembrane domain. GJB4-E204A impaired the binding with gap junction protein A1 (GJA1) compared with GJB4-WT. The expression of GJB4 was induced in rat disease models of left and right ventricle hypertrophy and mouse disease models of adriamycin-induced cardiomyopathy and myocardial infarction, while it was not detected at all in control. An immunohistochemical study was performed for autopsied human hearts and the explanted heart of the patient. GJB4 was expressed and colocalized with GJA1 in intercalated discs in human diseased hearts, which was extensively enhanced in the explanted heart of the patient. The abnormal expression and localization of GJB4 were observed in beating spheres of patient’s induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CMs). We generated knockout zebrafish of GJB4 by CRISPR/Cas9 and the endodiastolic volume and the ventricular ejection fraction were significantly lower in GJB4-deficient than in wild-type zebrafish at five days post-fertilization. These results indicate both that GJB4 is defined as a new connexin in diseased hearts, of which mutation can cause a familial form of HCM, and that GJB4 may be a new target for the treatment of cardiac hypertrophy and dysfunction.

18 October 2019 in The Astrophysical Journal
Verified
Journal Article
Open access
KHKatsuhiro Hayashi
Katsuhiro Hayashi
TMTsunefumi Mizuno
Tsunefumi Mizuno
YFYasuo Fukui
Yasuo Fukui
RORyuji Okamoto
Ryuji Okamoto
HYHiroaki Yamamoto
Hiroaki Yamamoto
HSHidetoshi Sano
Hidetoshi Sano
We report a Fermi-LAT γ-ray analysis for the Chamaeleon molecular cloud complex using a total column density ( ) model based on the dust optical depth at 353 GHz ( ) with the Planck thermal dust emission model. Gamma rays with energy from 250 MeV to 100 GeV are fitted with the model as a function of , (α ≥ 1.0), to explicitly take into account a possible nonlinear / ratio. We found that a nonlinear relation, α ∼ 1.4, gives the best fit to the γ-ray data. This nonlinear relation may indicate dust evolution effects across the different gas phases. Using the best-fit model, we derived the CO-to- conversion factor ( ) and gas mass, taking into account the uncertainties of the model. The value of is found to be (0.63–0.76) ×1020 cm−2 K−1 km−1 s, which is consistent with that of a recent γ-ray study of the Chamaeleon region. The total gas mass is estimated to be (6.0–7.3) × 104 , of which the mass of additional gas not traced by standard or CO line surveys is 20%–40%. The additional gas amounts to 30%–60% of the gas mass estimated in the case of optically thin and has five to seven times greater mass than the molecular gas traced by CO. Possible origins of the additional gas are discussed based on scenarios of optically thick and CO-dark . We also derived the γ-ray emissivity spectrum, which is consistent with the local emissivity derived from Fermi-LAT data within the systematic uncertainty of ∼20%.

18 November 2024 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
NTNaoki Tsuboya
Naoki Tsuboya
HSHirofumi Sawada
Hirofumi Sawada
YMYoshihide Mitani
Yoshihide Mitani
HOHironori Oshita
Hironori Oshita
KOKazunobu Ohya
Kazunobu Ohya
MHMasahiro Hirayama
Masahiro Hirayama
We investigated whether the disruption of C-C motif chemokine receptor (CCR) 2 may attenuate the development of pulmonary arterial hypertension (PAH) in any rat models with the reversal of the associated pro-inflammatory state and vascular dysfunction, and synergize with a conventional pulmonary vasodilator. Using Ccr2(-/-) rats generated by CRISPR/Cas9, we investigated pulmonary hypertension (PH) in Ccr2(+/+) or Ccr2(-/-) rats treated with monocrotaline (MCT), SU5416/hypoxia (SuHx) and chronic hypoxia (CH). Ccr2(-/-) decreased the right ventricular systolic pressure, an index of right ventricular hypertrophy and mortality rate, and reversed increased expression of inflammatory cytokines/chemokines (interleukin-6, tumor necrosis factor-α, C-C motif chemokine receptor (CCL)-2, interleukin-1β, transforming growth factor-β) in rats 3weeks after MCT injection, but not in SuHx or CH models. Consistently, Ccr2(-/-) decreased indices of pulmonary vascular diseases (PVD) and perivascular macrophage infiltration, as well as reversed impaired bone morphogenetic protein receptor type 2 signaling, increased endothelial apoptosis and impaired nitric oxide signaling and decreased phosphodiesterase-5 (PDE5) expression in lungs in MCT-treated rats. Gene expression of receptors for prostaglandin I2 and endothelin was not changed by Ccr2(-/-) in MCT-treated rats. In cultured pulmonary arterial smooth muscle cells (PASMCs), Ccr2(-/-) suppressed CCL2-induced hyperproliferation and dedifferentiation as well as reversed CCL2-induced decrease in PDE5 expression. The whole-genome RNA sequencing analysis identified differentially expressed genes in CCL2-stimulated Ccr2(-/-) PASMCs, which are related to regulation of cellular differentiation and contraction. Based on studies in rats and cultured PASMCs, we investigated whether a PDE5 inhibitor, tadalafil, synergizes with Ccr2(-/-). Tadalafil administration ameliorated PH and PVDs in MCT-treated Ccr2(-/-) rats but not in Ccr2(+/+) rats. Tadalafil further improved survival in MCT-treated Ccr2(-/-) rats. The present findings demonstrated that CCR2 disruption ameliorated PAH in MCT-treated rats, which was associated with the reversal of dysregulated inflammatory pathways and vascular dysfunction and synergized with tadalafil. These findings suggest that CCR2 may be a therapeutic target in intractable PAH patients with a certain CCR2-related inflammatory phenotype and refractory to conventional pulmonary vasodilators.

10 April 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ASAya Saiki
Aya Saiki
MOMichio Otsuki
Michio Otsuki
DTDaisuke Tamada
Daisuke Tamada
TKTetsuhiro Kitamura
Tetsuhiro Kitamura
ISIichiro Shimomura
Iichiro Shimomura
MNMitsuhide Naruse
Mitsuhide Naruse
Context: The prevalence of diabetes mellitus (DM) in patients with primary aldosteronism (PA) is higher than in those with essential hypertension and the general population. Although DM is a common major risk factor for cardio-cerebrovascular (CCV) diseases and renal complications, details of its effects in PA have not been demonstrated. Objective: The aim of this study was to determine the effects of coexistent DM on the risk of CCV events and progression of renal complications in PA patients. Design: A multi-institutional, cross-sectional study was conducted. Patients and Methods: PA patients experienced between January 2006 and October 2016 and with available data of CCV events and DM were enrolled from the Japan PA registry of the Japan Primary Aldosteronism Study/Japan Rare Intractable Adrenal Diseases Study (n = 2524). CCV events and renal complications were compared between a DM group and a non-DM group by logistic and liner-regression analysis. Results: DM significantly increased the odds ratio (OR) of CCV events (OR 1.59, 95% CI: 1.05-2.41) and that of proteinuria (OR 2.25, 95% CI: 1.59-3.16). DM correlated significantly with declines in estimated glomerular filtration rate (β = .05, P = .02). Conclusions: This the first report to demonstrate the presence of DM as an independent risk factor for CCV events and renal complications, even in PA patients. Management of DM should be considered in addition to the specific treatment of PA.